Skip to main content

Table 3 Performance of renal arrest biomarkers for predicting septic AKI progression or AKI progression with death in single or combination with renal damage biomarkers

From: Combining renal cell arrest and damage biomarkers to predict progressive AKI in patient with sepsis

Outcomes AUC 95% CI
AKI progression
 u[TIMP-2]*[IGFBP7] 0.745 0.667 to 0.823
 u[TIMP-2]*[IGFBP7] + uKIM-1 0.752 0.675 to 0.828
 u[TIMP-2]*[IGFBP7] + uIL-18 0.747 0.669 to 0.825
 u[TIMP-2]*[IGFBP7] + uACR 0.745 0.668 to 0.823
 u[TIMP-2]*[IGFBP7] + uKIM-1 + uIL-18 + uACR 0.755 0.679 to 0.832
AKI progression with death
 u[TIMP-2]*[IGFBP7] 0.777 0.700 to 0.854
 u[TIMP-2]*[IGFBP7] + uKIM-1 0.782 0.705 to 0.859
 u[TIMP-2]*[IGFBP7] + uIL-18 0.777 0.700 to 0.854
 u[TIMP-2]*[IGFBP7] + uACR 0.778 0.700 to 0.855
 u[TIMP-2]*[IGFBP7] + uKIM-1 + uIL-18 + uACR 0.780 0.703 to 0.857
  1. AKI progression is defined as worsening of AKI stage
  2. Abbreviation: AUC area under the receiver-operating characteristic curve, CI confidence interval; u[TIMP-2]*[IGFBP7], urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7; uKIM-1, urinary kidney injury moleculer-1; uIL-18, urinary Interleukin-18; uACR, urinary albumin to creatinine ratio